Cantor Fitzgerald Reiterates Overweight on Soleno Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Soleno Therapeutics (NASDAQ:SLNO) and maintained a price target of $67.
September 20, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Soleno Therapeutics, maintaining a $67 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests a positive outlook for Soleno Therapeutics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100